Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




2011 BIO International Convention Sets Attendance Records

By LabMedica International staff writers
Posted on 06 Jul 2011
The 2011 BIO International Convention, the largest global event for the biotechnology industry, set new records in partnering meetings, and increased international attendance and participation. More...
The convention program included panel sessions on the latest scientific, policy and business opportunities and challenges facing the industry. The conference, hosted by the Biotechnology Industry Organization (BIO; Washington DC, USA) in Washington DC (USA), drew 15,626 industry leaders from the US and other 65 countries.

“The 2011 BIO International Convention was an enormous success, bringing together leaders from industry, government, and academia who are working to solve some of the sector’s biggest challenges,” said President and CEO of BIO Jim Greenwood. “Bringing the global biotech industry to Washington DC, [USA], gave us the critical opportunity to showcase to key policymakers our industry’s promise to offer real solutions to the most pressing global challenges such as curing disease, reducing health care costs, combating hunger, discovering alternative forms of energy and creating high-wage jobs. We continue to advocate for a policy and regulatory environment that will support innovation and inspire industry growth.”

Keynote sessions included the former UK Prime Minister Tony Blair, US Senator John Barrasso, former US Senator Tom Daschle, Vermont Governor Howard Dean, and Republican political strategist Karl Rove. The Convention program featured more than 125 sessions across 15 tracks, including Global Innovations and Markets, Health Policy and Reimbursement, Biosecurity, Business Development, Food and Agriculture, and Biofuels, and Biobased Chemicals.

The BIO Business Forum hosted a record-breaking 21,183 partnering meetings between 2,410 companies and featured 157 company presentations. According to the BIO Business Forum Partnering Report there is high demand for Phase I assets as well as Central Nervous System (CNS), immunology, and metabolic therapeutic areas compared to 2010. In addition, the 2010 top-three-highest interest therapeutic areas in including cardiovascular, oncology, and respiratory categories are now all in the bottom half of 2011's top 10 areas.

The 2012 BIO International Convention will take place during June 18-21, 2012, at the Boston Convention and Exhibition Center in Boston (MA, USA).

Related Links:
BIO International Convention
Biotechnology Industry Association



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.